Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure

Yanfei WANG; Juan MA; Yunqiao YANG

doi:10.12259/j.issn.2095-610X.S20221117

Volume 43 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2022 > 43(11): 136-140

Yanfei WANG, Juan MA, Yunqiao YANG. Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure[J]. Journal of Kunming Medical University, 2022, 43(11): 136-140. doi: 10.12259/j.issn.2095-610X.S20221117

Citation:

Yanfei WANG, Juan MA, Yunqiao YANG. Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure[J]. Journal of Kunming Medical University, 2022, 43(11): 136-140. doi: 10.12259/j.issn.2095-610X.S20221117

Citation:

Yanfei WANG, Juan MA, Yunqiao YANG. Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure[J]. Journal of Kunming Medical University, 2022, 43(11): 136-140. doi: 10.12259/j.issn.2095-610X.S20221117

PDF( 612 KB)

Clinical Efficacy and Safety of Sacubatril Valsartan in Patients with Reduced Ejection Fraction Combined with Hypotensive Heart Failure

doi: 10.12259/j.issn.2095-610X.S20221117

Dept.of Cardiology，The First People’s Hospital of Kunming，Kunming Yunnan 650011，China

Received Date: 2022-05-20
Available Online: 2022-10-29
Publish Date: 2022-11-14

Abstract

Abstract

Objective To observe the clinical efficacy and safety of sacubitril-valsartan in patients with reduced ejection fraction and hypotensive heart failure. Methods A total of 100 patients with decreased ejection fraction combined with hypotension and heart failure who were admitted to the Department of Cardiology of Kunming First People’s Hospital from January 2020 to December 2021 were included in the study. The patients were randomly divided into an observation group and a control group, with 50 cases in each group. The patients in the two groups were given standard treatment for heart failure including diuresis and β -receptor blockers. The patients were given sacubatril valsartan at a small dose of 25–50 mg twice a day. According to the patient’s tolerance, the dose was doubled and increased once every 2–4 weeks until the maintenance dose was reached. After 12 months of treatment, the LVEF, LVDd and LVDs of cardiac function in two groups were compared before and after treatment, and the SBP, DBP, blood K+, blood Na+, CTNT, NT-proBNP were observed. Results After treatment, the LVEF of patients in the two groups was increased, while the LVDd and LVDs were decreased. There was statistical difference in LVEF and LVDs between the two groups （P < 0.05）, but no statistical difference in LVDd （P > 0.05）. After treatment, the levels of blood K+, blood Na+, and CTNT increased in the two groups , there was no significant difference between the two groups after treatment （P > 0.05）; NT proBNP decreased significantly after treatment （P < 0.05）. After treatment, the systolic blood pressure in the experimental group increased compared with that before treatment, while there was no significant change in the control group （P > 0.05）, and there was no significant difference in diastolic blood pressure between the two groups （P > 0.05）. Conclusion The treatment of HFrEF combined with hypotension in patients taking sacubatril valsartan can improve heart function, it has no effect on blood pressure, and is safe.
- HFrEF,
- Hypotension,
- Sacubatril valsartan sodium tablets,
- Clinical efficacy,
- Blood pressure

FullText(HTML)

References(15)

References

[1]	Murphy S P,Ibrahim N E,Januzzi J L Jr. Heart failure with reduced ejection fraction:A review[J]. JAMA,2020,324(5):488-504. doi: 10.1001/jama.2020.10262
[2]	华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志,2018,46(10):760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
[3]	高语薇. 慢性心力衰竭的诊断和临床治疗进展[J]. 贵州医药,2019,43(10):1539-1542. doi: 10.3969/j.issn.1000-744X.2019.10.008
[4]	郭鑫鑫,常冰. 血管紧张素受体脑啡肽酶抑制剂治疗射血分数中间值心力衰竭的疗效分析[J]. 心肺血管病杂志,2021,40(1):21-23. doi: 10.3969/j.issn.1007-5062.2021.01.005
[5]	中国老年医学学会心电及心功能分会,中国医师协会心血管内科分会,中国心衰中心联盟专家委员会. 慢性心力衰竭加重患者的综合管理中国专家共识2022[J]. 中国循环杂志,2022,37(3):215-225. doi: 10.3969/j.issn.1000-3614.2022.03.003
[6]	MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)[J]. Lancet,1999,353(9169):2001-2007. doi: 10.1016/S0140-6736(99)04440-2
[7]	石宇杰,王剑飞,韩运峰,等. 沙库巴曲缬沙坦治疗射血分数保留心功能衰竭的疗效研究[J]. 中国循证心血管医学杂志,2020,12(1):88-91.
[8]	张辉,周文平,刘刚琼,等. 沙库巴曲缬沙坦与依那普利对缺血型心肌病患者血流介导的血管扩张功能及颈动脉内中膜厚度的影响[J]. 临床心血管病杂志,2018,34(5):42-44.
[9]	刘岳,汪芳. 沙库巴曲缬沙坦的药代动力学和药效学特点[J]. 中国循环杂志,2018,36(2):184-186.
[10]	McMurray J J,Packer M,Desai A S,et al. Angiotensin neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(11):993-1004. doi: 10.1056/NEJMoa1409077
[11]	Velazquez E J,Morrow D A,DeVore A D,et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med,2019,380(6):539-548. doi: 10.1056/NEJMoa1812851
[12]	中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 慢性心力衰竭基层诊疗指南(2019年)[J]. 中华全科医师杂志,2019,18(10):948-956. doi: 10.3760/cma.j.issn.1671-7368.2019.10.009
[13]	Böhm M,Young R,Jhund P S,et al. Systolic blood pressure,cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction:Results from PARADIGM-HF[J]. Eu HeartJ,2017,38(15):1132-1143. doi: 10.1093/eurheartj/ehw570
[14]	Selvaraj S,Chggett B L,Bo}lm M,et a1. Syst01ic blood pressure in heart failure with preserved ejection Fraction treated with sacubitril/Valsartan[J]. J Am CoU Cardiol,2020,75(14):1644-1656. doi: 10.1016/j.jacc.2020.02.009
[15]	赵小丽,钱孝贤,谢旭晶. 血压与慢性心力衰竭预后及管理的研究进展[J]. 心肺血管病杂志,2022,41(1):103-105. doi: 10.3969/j.issn.1007-5062.2021.01.021

Relative Articles(20)

Relative Articles

[1]	Ling ZHAO, Hongling ZHONG, Xinru GAO, Mei LI, Tingting MAO, Rongyong LI, Tingyu KE. Clinical Observation of SGLT-2 Inhibitors in Delaying the Progression of Diabetic Nephropathy. Journal of Kunming Medical University, 2023, 44(5): 60-65. doi: 10.12259/j.issn.2095-610X.S20230527
[2]	Weiqiang ZHANG, Fang LUO, Chunhua ZHU, Dezhi TANG. Analysis of Correlations of Age，Diseases and Blood Pressure Based on a Population of 82782 Individuals. Journal of Kunming Medical University, 2023, 44(10): 107-113. doi: 10.12259/j.issn.2095-610X.S20231003
[3]	Zhang Ti Ling , Zhang Wei Hua , Luo Qing 祎, Xia Hong Ying , Lu Yi Bing . . Journal of Kunming Medical University, 2020, 41(03): 91-95.
[4]	Lai 碁, Guang Xue Feng , Jing Shu Nan , Chen Zhi Peng , He Chen De , Lin Chun Rong , Lv Ning , Sun Yun Hua . Significance of Invasive Pressure Monitoring in Low Blood Pressure of Dominant Right Coronary Artery after STEMI PPCI. Journal of Kunming Medical University, 2017, 38(04): 45-48.
[5]	Wang Juan . Influence of Comprehensive Nursing Intervention on Clinical Efficacy and Complications of Patients with Nephrotic Syndrome. Journal of Kunming Medical University,
[6]	Chen Nan . Observation on the Clinical Efficacy between Pemetrexed Plus Cisplatin and Paclitaxel Plus Cisplatin in the Treatment of Advanced Non-small Eell Lung Cancer. Journal of Kunming Medical University,
[7]	Cao Yun . Prevention and Treatment of Intraoperative Hypotension with Combined Spinal-epidural Anesthesia for Cesarean Section. Journal of Kunming Medical University,
[8]	Zhang Qiong Yu . . Journal of Kunming Medical University,
[9]	Zhang Li Juan . . Journal of Kunming Medical University,
[10]	Li Wen Hong . . Journal of Kunming Medical University,
[11]	Fan Xiu E . . Journal of Kunming Medical University,
[12]	Kang Ying Hong . . Journal of Kunming Medical University,
[13]	Gai Qi Ming . . Journal of Kunming Medical University,
[14]	Fu Zhong Yang . . Journal of Kunming Medical University,
[15]	Duan Xian Meng . . Journal of Kunming Medical University,
[16]	Yang Zheng . . Journal of Kunming Medical University,
[17]	Song Hua . . Journal of Kunming Medical University,
[18]	Tao Zhi Xing . Comparison of Clinical Efficacy between Holmium Laser and Pneumatic Ballistic Lithotripsy in Treatment of Kidney Stones. Journal of Kunming Medical University,
[19]	Jie Yan Hua . Chest X-ray Radiographic and CT Findings in Severe A (H1N1)Virus Infection. Journal of Kunming Medical University,
[20]	. Treatment of 15 Patients with Hypertension Accompanied by Coronary Heart Disease with Combination of Isosorbide Mononitrate and Levamlodipine. Journal of Kunming Medical University,